Dr. Lal PathLabs (NSE:LALPATHLAB) Construction In Progress: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LALPATHLAB Dr. Lal PathLabs Ltd NSE:LALPATHLAB
93 GF Score
Price ₹1,949.90
GF Value ₹1,735.83
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Dr. Lal PathLabs Construction In Progress?

Dr. Lal PathLabs NSE:LALPATHLAB -0.21% 93 Construction In Progress is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Dr. Lal PathLabs's quarterly construction in progress increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹59 Mil) but then declined from Mar. 2026 (₹59 Mil) to Jun. 2026 (₹0 Mil).

Dr. Lal PathLabs's annual construction in progress increased from Mar. 2024 (₹54 Mil) to Mar. 2025 (₹69 Mil) but then declined from Mar. 2025 (₹69 Mil) to Mar. 2026 (₹59 Mil).

Dr. Lal PathLabs Construction In Progress Historical Data

* Premium members only.

The historical data trend for Dr. Lal PathLabs's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr. Lal PathLabs Construction In Progress Chart

Dr. Lal PathLabs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 159.33 39.15 53.71 68.57 59.49

Dr. Lal PathLabs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 166.00 0.00 59.49 0.00
NSE:LALPATHLAB
93GF Score
Dr. Lal PathLabs Ltd NSE:LALPATHLAB
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr. Lal PathLabs Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹0 Mil mean?
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Construction In Progress of ₹0 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Dr. Lal PathLabs and its competitors.
Is Dr. Lal PathLabs' Construction In Progress too high?
Dr. Lal PathLabs' current Construction In Progress is ₹0 Mil. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Construction In Progress compare to TMO and DHR?
Dr. Lal PathLabs' Construction In Progress of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Diagnostics & Research company?
A good Construction In Progress depends on the Medical Diagnostics & Research industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Dr. Lal PathLabs and its competitors. Dr. Lal PathLabs's current Construction In Progress is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Construction In Progress is ₹0 Mil. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Construction In Progress is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued. The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83. GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.

Key valuation signals for NSE:LALPATHLAB:

  • Construction In Progress: ₹0 Mil
  • GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr. Lal PathLabs Business Description

Other Exchanges 539524:India
Address 12th Floor, Tower B, SAS Tower, Sector 38, Medicity, Gurugram, HR, IND, 122 001
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score

Get the complete analysis for NSE:LALPATHLAB

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,949.90
Price
₹1,735.83
GF Value